Document is current
Any future updates will be listed below
-
Authors
Mandaric, Sanja
Friberg, Heather https://orcid.org/0000-0001-5173-2701
Saez-Llorens, Xavier https://orcid.org/0000-0002-1149-5905
Borja-Tabora, Charissa
Biswal, Shibadas https://orcid.org/0000-0001-5077-4838
Escudero, Ian https://orcid.org/0009-0000-5254-6396
Faccin, Alice
Gottardo, Raphael
Brose, Manja https://orcid.org/0009-0002-2741-4855
Roubinis, Nicholas
Fladager, Darlene
DeAntonio, Rodrigo
Dimero, Julie Anne L.
Montenegro, Nathali
Folschweiller, Nicolas
Currier, Jeffrey R.
Sharma, Mayuri
Tricou, Vianney https://orcid.org/0000-0002-5465-8647
-
Funding
Funding for this research was provided by:
Takeda Pharmaceutical Company
- License Information
-
More Information
Article History
Received: 15 March 2024
Accepted: 11 September 2024
First Online: 17 October 2024
Competing interests
: The Authors declare the following competing financial and non-financial interests: S.M., S.B., A.F., I.E., D.F., N.R., N.F., M.S., M.B., and V.T. are employees of Takeda and may hold stock/stock options in Takeda. H.F. and J.R.C. received funds from Takeda for T-cell testing through a Cooperative Research and Development Agreement (CRADA) between Takeda Vaccines and WRAIR. C.B.-T., X.S.-L., R.G., J.A.L.D., R.D.A., and N.M. received institutional research funds from Takeda for study-related activities. Material has been reviewed by the Walter Reed Army Institute of Research. There is no objection to its presentation and/or publication. The opinions or assertions contained herein are the private views of the authors, and are not to be construed as official, or as reflecting true views of the Department of the Army or the Department of Defense. The investigators have adhered to the policies for the protection of human subjects as prescribed in AR 70–25.
